MagForce AG: MagForce USA, Inc. Completed Enrollment and Treatment for Stage 1 and Prepares for Next Stage of its Pivotal, Single-Arm Study for the Focal Ablation of Intermediate Risk Prostate Cancer with NanoTherm Therapy Written by Petra Hegmann on 27th August 2019. Posted in Client News. Previous Next